Biogen Inc. is a multinational biotechnology company specializing in the treatment of neurological diseases. Its primary focus is on multiple sclerosis (MS), with key products including Tecfidera, Vumerity, Avonex, Plegridy, and Tysabri, which collectively account for 45% of 2024 revenues.